top of page

List of signals discussed at PRAC since September 2012

Each month the PRAC analyses, prioritises and evaluates safety signals concerning medicinal products authorised in the EU. This assessment may result in various recommendations, including an update of the product information (summary of product characteristics and package leaflet). The table below is a cumulative list of signals discussed at PRAC since its establishment. It is updated after each CHMP/CMDh meeting.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page